Study identifier:2993-120
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Phase 2
No
Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily
All
99
Interventional
18 Years - 75 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Eli Lilly and Company
No locations available
Arms | Assigned Interventions |
---|---|
Placebo Comparator: A1 - Placebo 0.04 mL twice daily | Drug: Placebo 0.04 mL twice daily Subcutaneously injected, 0.04 mL, twice daily |
Placebo Comparator: A2 - Placebo 0.04 mL once daily | Drug: Placebo 0.04 mL once daily Subcutaneously injected, 0.04 mL, once daily |
Placebo Comparator: A3 - Placebo 0.08 mL once daily | Drug: Placebo 0.08 mL once daily Subcutaneously injected, 0.08 mL, once daily |
Experimental: B - Exenatide 10 mcg twice daily | Drug: B - Exenatide 10 mcg twice daily Subcutaneously injected, 10 mcg (0.04 mL), twice daily Other Name: ACC2993 Other Name: synthetic exendin-4 |
Experimental: C - Exenatide 10 mcg once daily | Drug: C - Exenatide 10 mcg once daily Subcutaneously injected, 10 mcg (0.04 mL), once daily Other Name: ACC2993 Other Name: synthetic exendin-4 |
Experimental: D - Exenatide 20 mcg once daily | Drug: Exenatide 20 mcg once daily Subcutaneously injected, 20 mcg (0.08 mL), once daily Other Name: ACC2993 Other Name: synthetic exendin-4 |